Fast Diagnostics of BRAF Mutations in Biopsies from Malignant Melanoma
Source abstract
Abstract
According to the American skin cancer foundation, there are more new cases of skin cancer than the combined incidence of cancers of the breast, prostate, lung, and colon each year, and malignant melanoma represents its deadliest form. About 50% of all cases are characterized by a particular mutation BRAF(V600E) in the BRAF (Rapid Acceleration of Fibrosarcoma gene B) gene. Recently developed highly specific drugs are able to fight BRAF(V600E) mutated tumors but require diagnostic tools for fast and reliable mutation detection to warrant treatment efficiency. We completed a preliminary clinical trial applying cantilever array sensors to demonstrate identification of a BRAF(V600E) single-point mutation using total RNA obtained from biopsies of metastatic melanoma of diverse sources (surgical material either frozen or fixated with formalin and embedded in paraffin). The method is faster than the standard Sanger or pyrosequencing methods and comparably sensitive as next-generation sequencing. Processing time from biopsy to diagnosis is below 1 day and does not require PCR amplification, sequencing, and labels.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Melanoma and MAPK Pathways · Computational Drug Discovery Methods · bioluminescence and chemiluminescence research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Swiss Nanoscience Institute, Department of Physics, University of Basel, CH-4056 Basel, Switzerland
Institute of Pathology, University Hospital Basel, CH-4031 Basel, Switzerland
Ludwig Center for Cancer Research, University of Lausanne, CH-1066 Epalinges, Switzerland
Funding
Schweizerische Eidgenossenschaft · Schweizerische Hochschulkonferenz · Rat der Eidgenössischen Technischen Hochschulen
References (23)
Show source-provided references
1. 10.1002/ijc.2921010.1002/ijc.29210 ↗
2. 10.1016/j.canlet.2014.11.00110.1016/j.canlet.2014.11.001 ↗
3. 10.1016/j.clinthera.2012.06.00910.1016/j.clinthera.2012.06.009 ↗
4. 10.1016/j.cell.2015.05.04410.1016/j.cell.2015.05.044 ↗
5. 10.1038/nature1244110.1038/nature12441 ↗
6. Larkin J. M. G. · J. Clin. Oncol. · 2015 · 33 · 900610.1200/jco.2015.33.15_suppl.9006 ↗
7. 10.1016/j.gene.2008.09.01310.1016/j.gene.2008.09.013 ↗
8. 10.1103/PhysRevLett.56.93010.1103/PhysRevLett.56.930 ↗
9. 10.1126/science.288.5464.31610.1126/science.288.5464.316 ↗
10. 10.1021/ac001274810.1021/ac0012748 ↗
11. 10.1073/pnas.15233019910.1073/pnas.152330199 ↗
12. 10.1021/la048955910.1021/la0489559 ↗
13. 10.1088/0957-4484/14/1/31910.1088/0957-4484/14/1/319 ↗
14. 10.1073/pnas.050491710210.1073/pnas.0504917102 ↗
15. 10.1016/j.bios.2005.07.01810.1016/j.bios.2005.07.018 ↗
16. 10.1038/nnano.2013.12010.1038/nnano.2013.120 ↗
17. 10.1038/nnano.2006.13410.1038/nnano.2006.134 ↗
18. 10.1038/nnano.2012.26310.1038/nnano.2012.263 ↗
19. 10.1529/biophysj.105.07293410.1529/biophysj.105.072934 ↗
20. 10.1016/S0301-4622(00)00157-510.1016/S0301-4622(00)00157-5 ↗
21. 10.1093/nar/gkq107910.1093/nar/gkq1079 ↗
22. 10.1097/PDM.0b013e31823b216f10.1097/PDM.0b013e31823b216f ↗
23. 10.1016/j.ccr.2010.10.01210.1016/j.ccr.2010.10.012 ↗